Akkermansia Muciniphila Probiotics for Improved Gut Health

A composition for preventing or treating metabolic disorders, comprising pasteurized Akkermansia muciniphila and a green tea extract, for use in treating obesity, metabolic syndrome, insulin resistance, and other metabolic disorders. The composition is administered orally and can be used in food products, dietary supplements, or pharmaceuticals.

Source

A microbial combination for weight loss comprising Lactobacillus gasseri and Akkermansia muciniphila, with a specific ratio of 40-60 copies of each bacterium. The combination is prepared by culturing the bacteria in separate media and then combining them in a pharmaceutical composition for oral administration. The composition is used to treat obesity and related metabolic disorders, such as hypertension, hyperlipidemia, and diabetes.

Source

The gut microbiota is an indispensable component of the proper functioning of the human body, as gut microorganisms and their metabolites strongly influence the host's metabolism and immune functions. They also contribute to the biosynthesis of vitamins, production of gut hormones, maintenance of intestinal barrier integrity, protection against pathogens, as well as digestion and absorption of nutrients. Increasingly, the relationship between disturbances in the composition of gut microbiota and the onset of metabolic diseases such as obesity and type 2 diabetes is being emphasized. Understanding the significance of the microbiota in the course of these diseases, its composition, and activity may offer new approaches to their treatment. Increasing attention is being paid to individual species of gut bacteria, among which Akkermansia muciniphila holds a special position, as a decrease in the abundance of this commensal bacterium in the gut is associated with many diseases, including obesity and diabetes.

Source

A diet-reducing capsule containing multi-nutrient microspheres that simultaneously supports weight loss, nutritional supplementation, intestinal health, and probiotic colonization. The capsule combines hydrogel particles with probiotic-prebiotic-vitamin-mineral microspheres, which adhere to the hydrogel surface or are sandwiched between the particles. This microsphere matrix provides a stable environment for probiotic survival and absorption, while the hydrogel maintains its structure. The capsule is freeze-dried to preserve the microspheres' functionality, allowing them to release their active components over time. The combination of probiotics, vitamins, and minerals in the capsule provides a comprehensive nutritional support system for weight management, while the probiotics enhance gut health and satiety.

Source

Methods and compositions for treating weight-related disorders by altering the gut microbiota. The methods involve administering microbiota from specific bacterial phyla, orders, or genera to increase their relative abundance in the gut, thereby promoting weight loss and improving metabolic health. The compositions can include live bacterial strains or compounds that selectively increase or decrease specific microbiota populations. The methods can be used as a standalone treatment or in combination with other therapies, including surgery, to manage obesity and related metabolic disorders.

Source

A novel strain of Akkermansia muciniphila, designated as SSYD-3, for preventing and treating metabolic diseases. The strain exhibits improved fermentation performance, storage stability, acid and bile resistance compared to the existing ATCC BAA835 strain. It is effective in reducing visceral adipose tissue, improving oral glucose tolerance, and enhancing insulin sensitivity, making it a promising therapeutic agent for obesity, type 2 diabetes, and metabolic syndrome.

Source

A composition for improving intestinal microbial populations and reducing body weight, comprising galactose, which increases the proportion of beneficial bacteria such as Akkermansia, Lactobacillus, and Alistipes, and is used for preventing and treating obesity.

Source

The anaerobic bacterium Akkermansia muciniphila has demonstrated its role in regulating metabolism and markers of inflammation since its discovery. It is a Gram-negative bacteria that is classified within the phylum Verrucomicrobiae. It is recognized as a non-pathogenic bacteria, devoid of virulence factors and lacking a significant interaction with the host that leads to infection or disease. It is part of the human intestinal microbiome and its highest concentration is found in individuals of normal weight. A systematic review was performed to analyze clinical dietary interventions examining the association between obesity phenotype or status and the concentration of A. muciniphila in the intestinal microbiota, after specific nutritional modifications in overweight human patients. The search for articles was carried out using Pubmed and Clinicalkey as search engines. The Boolean terminology ((Akkermansia muciniphila) and (obesity)) and (intervention or nutrition or diet or nutrient) was used to select articles relevant to our research. Of the 301 original articles identified, only ... Read More

Source

The relationship between gut microbiota and obesity has recently been an important subject for research as the gut microbiota is thought to affect body homeostasis including body weight and composition, intervening with pro and prebiotics is an intelligent possible way for obesity management. To evaluate the effect of hypo caloric adequate fiber regimen with probiotic supplementation and physical exercise, whether it will have a good impact on health, body composition, and physique among obese Egyptian women or has no significant effect. The enrolled 58 women, in this longitudinal follow-up intervention study; followed a weight loss eating regimen (prebiotic), including a low-carbohydrate adequate-fiber adequate-protein dietary pattern with decreased energy intake. They additionally received daily probiotic supplements in the form of yogurt and were instructed to exercise regularly for 3 months. Anthropometric measurements, body composition, laboratory investigations, and microbiota analysis were obtained before and after the 3 months weight loss program. Statistically highly signifi... Read More

Source

Metabolic diseases are comprehensive disease based on obesity. Numerous cumulative studies have shown a certain correlation between the fluctuating abundance of Akkermansia muciniphila and the occurrence of metabolic diseases. A. muciniphila , a potential probiotic candidate colonized in the human intestinal mucus layer, and its derivatives have various physiological functions, including treating metabolic disorders and maintaining human health. This review systematically explicates the abundance change rules of A. muciniphila in metabolic diseases. It also details the high efficacy and specific molecules mechanism of A. muciniphila and its derivatives in treating obesity, type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease.

Source

Methods for treating metabolic disorders by administering a therapeutically-effective amount of a pharmaceutical composition comprising a population of isolated and purified microbes, wherein at least one of the microbes has a specific sequence identity to a rRNA sequence of a particular microbe species. The composition can comprise microbes that alter glucagon-like peptide-1 (GLP-1) production, encode for enzymes involved in butyrate production, or produce butyrate. The microbes can be selected based on their rRNA sequence identity to specific species, including Akkermansia muciniphilia, Anaerostipes caccae, and Bifidobacterium adolescentis.

Source

More than half of the states in the U.S. report that over 30% of adults are obese. Obesity increases the risk of many chronic diseases, including type 2 diabetes, hypertension, cardiovascular disease, and can even reduce ones lifespan. Similarly, the prevalence of type 2 diabetes follows a comparable trend. As a result, researchers are striving to find solutions to reduce obesity rates, with a particular focus on gut health, which has been previously linked to both obesity and type 2 diabetes. Recent studies suggest that Akkermansia muciniphila(AKK) may have a positive probiotic effect on preventing the onset of type 2 diabetes and obesity. We conducted a quantitative meta-analysis of 15 qualified animal studies investigating the effects of AKK administration as a probiotic. The statistical analyses showed that AKK administration significantly reduced body weight gain by 10.4% and fasting blood glucose by 21.2%, while also significantly improving glucose tolerance by 22.1% and increasing blood insulin levels by 26.9%. However, our analysis revealed substantial heterogeneity between ... Read More

Source

Abstract As one of the most attractive nextgeneration probiotics, mucindegrading Akkermansia muciniphila has emerged as an essential and integral factor in maintaining human health and affecting pathological outcomes. Its abundance is inversely associated with various metabolic diseases (e.g., obesity and type 2 diabetes), cardiovascular diseases, and intestinal inflammation. Supplementing A. muciniphila to restore the gut microbiota ecosystem is a promising approach for treating metabolic disorders. However, the direct utilization of this probiotic is limited by technological and regulatory hurdles, such as the in vitro bulk culture of A. muciniphila and the need for expensive animalderived materials. Therefore, enrichment of A. muciniphila using nutraceutical supplements is a feasible strategy. Dietary supplements, especially medicinal herbs, offer a vast and valuable resource as potential prebiotics for promoting the growth of A. muciniphila in the gut, ensuring reliable safety and efficacy. In this study, we first systemically reviewed the dietary substances and medicinal food... Read More

Source

In the present study, next generation probiotic Akkermansia muciniphila was incorporated into a dairy matrix containing Portuguese whey cheese and Greek-style yoghurt in a proportion of 3.5:1, respectively. Subsequently, this innovative food was characterized in terms of microbiological and physicochemical parameters, total phenolic content and antioxidant, antidiabetic, and antihypertensive activities, as well as its protective effect on A. muciniphila viability during 21 d of refrigerated aerobic storage and when subjected to simulated gastrointestinal passage. The probiotic cheese spread displayed high microbiological quality, low total phenolic content (0.36 mg gallic acid equivalents/g of dried cheese) and interesting biological activities, including antidiabetic (98.10% -glucosidase inhibition) and antihypertensive (49.18% angiotensin converting enzyme inhibition). Simultaneously, this food ensured a high A. muciniphila viability (>108 CFU/g) during 21 d of refrigerated aerobic storage with subsequent in vitro digestion. Additionally, this probiotic cheese presented a similar ... Read More

Source

A bacterium known as Akkermansia muciniphila (AkkermansiaA. muciniphila) was detected in human feces in 2004. It is defined as a gram-negative, anaerobic, and mucin-degrading microbe belonging to the Verrucomicrobia species. Although the majority of A. muciniphila is found in the human intestinal tract playing a role in the gut microbiome, there are also smaller levels detected in breast milk and oral cavities as well as in the pancreas and appendix.Evidence suggests that having A. muciniphila present in the gut microbiome has positive effects on human health. As a result, A. muciniphila has been shown to have health benefits when taken as a dietary supplementation where it is considered a promising next-generation probiotic. However, the large-scale production of A. muciniphila remains a challenge due to its need for a stable environment. While culturing A. muciniphila in a mucin-based medium is one option, other strategies that use plate-based mediums have also been explored. Currently, both live and pasteurized forms of A. muciniphila are available on the market and shown to have ... Read More

Source

Abstract Background The prevalence of excess weight and obesity is increasing in an extremely concerning manner worldwide, with highly diverse therapies for current treatment. This review evaluated the scientific evidence of the past 10 years on the use of probiotics in treating excess weight and obesity in the absence of dieting. Materials A systematic review was conducted by searching for clinical trials on humans published in English in the PubMed, Scopus and Cochrane Central databases, using the combination of keywords Overweight, Probiotics and Obesity, and published between 2012 and 2022. Results Six published studies met the inclusion criteria. The review showed that, although there is a lack of consensus in the literature, the use of probiotics in the absence of dieting produced a significant reduction in body weight and body mass index in 66.6% of the reviewed studies, a significant reduction in waist circumference in 80.0% of the reviewed studies, and an improvement in total body fat mass and waist circumference. Conclusions This review showed evidence of a trend in p... Read More

Source

Akkermansia muciniphila and Faecalibacterium prausnitzii are next-generation probiotics, which has been reported to protect disease and effectively utilize various carbohydrates (starch and pectin) as nutrients for growth. Atemoya exhibiting fruity flavor, which is suitable for enhancing aroma and attenuating unpleasant taste caused by the koji metabolites. Results indicated that malic acid was increased (from 42.4 to 70.1 mg/100 g) in fermented Atemoya-Amazake. In addition, fermented Atemoya-Amazake elevated growthes in A. muciniphila and F. prausnitzii. Similarly, the populations of Parabacteroides (5.7 fold) and Akkermansia (1.66 fold) were elevated by fermented Atemoya-Amazake treatment in an in vitro simulated gastrointestinal system compared to the control group. Results revealed that fermented Atemoya-Amazake modulated the intestinal microbiota through increasing the production of short-chain fatty acids (exhibiting anti-pathogenic activity) for 2.1, 2.5, 2.6, and 2.1 folds in acetic acid, propionic acid, isobutyric acid, and butyric acid, respectively; suggesting this ferment... Read More

Source

Obesity is a global health concern associated with a wide range of diseases, including diabetes, metabolic syndrome, fatty liver, and cardiovascular conditions. Recent studies highlight the significant role of gut microbiota in obesity. Research indicates notable changes in the composition and diversity of gut microbiota in individuals diagnosed with obesity. The gut microbiota participate in energy metabolism, lipid synthesis, and regulation of inflammation and therefore play a key role in the pathogenesis of obesity. Therapeutic approaches based on the use of probiotics, prebiotics, Akkermansia muciniphila, and fecal microbiota transplantation have shown promise in animal studies as useful strategies against obesity and metabolic syndrome. However, further research is warranted to conclusively establish the specific strains, dosages, and mechanisms underlying the effectiveness of these novel strategies against obesity in humans.

Source

Akkermansia muciniphila is a gram-negative anaerobic bacterium, which represents a part of the commensal human microbiota. Decline in the abundance of A. muciniphila among other microbial species in the gut correlates with severe systemic diseases such as diabetes, obesity, intestinal inflammation and colorectal cancer. Due to its mucin-reducing and immunomodulatory properties, the use of probiotics containing Akkermansia sp. appears as a promising approach to the treatment of metabolic and inflammatory diseases. In particular, a number of studies have focused on the role of A. muciniphila in colorectal cancer. Of note, the results of these studies in mice are contradictory: some reported a protective role of A. muciniphila in colorectal cancer, while others demonstrated that administration of A. muciniphila could aggravate the course of the disease resulting in increased tumor burden. More recent studies suggested the immunomodulatory effect of certain unique surface antigens of A. muciniphila on the intestinal immune system. In this Perspective, we attempt to explain how A. mucinip... Read More

Source

Compositions comprising at least one strain of Akkermansia muciniphila, characterized by diverse capsular types, biofilm formation, and activation of innate immune pathways, and methods of using these compositions to alter the gut microbiota and treat diseases such as obesity, metabolic disorders, and inflammatory conditions.

Source

The pathogenesis of obesity has been linked to alterations in gut microorganisms. The aim of this study was to investigate the effect of Lactobacillus kefiri, together with PENS T6 and a hypocaloric diet, on weight loss, hypertension and laboratory glycemic and lipid profile. A prospective non-randomized study was conducted involving adult patients with a body mass index (BMI) > 30 kg/m2. Patients were divided into two groups: those undergoing PENS-T6 and hypocaloric diet (PENS-Diet Group) and those undergoing the same PENS-T6 scheme and hypocaloric diet, but additionally receiving probiotics including Lactobacillus kefiri (PENS-Diet + L. kefiri Group). Weight loss was assessed at the end of the treatment, and analytical glycemic and lipid profile, and microbiological analysis of feces were performed before and after treatment. The addition of Lactobacillus kefiri to PENS T6 and a low-calorie diet, increases weight loss and further improves the glycemic and lipid profile. L. kefiri also causes a further improvement in obesity-associated dysbiosis, mainly by increasing the muconutr... Read More

Source

Akkermansia muciniphila, a frequent colonizer in the gut mucous layer of individuals, has constantly been recognized as a promising candidate for the next generation of probiotics due to its biological advantages from in vitro and in vivo investigations. This manuscript comprehensively reviewed the features of A. muciniphila in terms of its function in host physiology and frequently utilized nutrition using the published peer-reviewed articles, which should present valuable and critical information to scientists, engineers, and even the general population. A. muciniphila is an important bacterium that shows host physiology. However, its physiological advantages in several clinical settings also have excellent potential to become a probiotic. Consequently, it can be stated that there is a coherent and direct relation between the biological activities of the gut microbiota, intestinal dysbiosis/eubiosis, and the population of A. muciniphila in the gut milieu, which is influenced by various genetical and nutritional factors. Current regulatory barriers, the need for large-scale clinical... Read More

Source

Introduction: The complex symbiotic connection between the host and the gut microbiome, which has many important functions in the organism, provides an opportunity for dysbiosis to potentially serve as a catalyst for various health disorders. Akkermancia muciniphila, a bacterium that degadates mucin, is a noteworthy element of the human gut microbiome and has captured the attention of researchers due to its correlation with numerous diseases.
 Aim of the study: The purpose of this research was to review literature and determine the impact of Akkermansia muciniphila in selected diseases. A systematic review was conducted using PubMed database.
 State of knowledge: Studies have shown that reduced numbers of Akkermansia muciniphila have been associated with many diseases, including obesity, type 2 diabetes, atherosclerosis, fatty liver, some neurological conditions, inflammation, and response to cancer immunotherapies. Furthermore, the administration of this bacterium has been shown to have a positive impact on reducing obesity-related parameters, improving insulin sensitivity... Read More

Source

A nutritional supplement that enhances weight loss through a synergistic approach involving probiotics, prebiotics, postbiotics, and plant extracts. The supplement combines a probiotic strain with a prebiotic fiber and a plant extract that modulates dopamine and adenosine pathways, all of which work together to improve gut-brain communication and metabolic function. The supplement is designed to support weight loss, improve mood, and enhance overall health through these mechanisms, with a proven track record of achieving significant weight loss results.

Source

Probiotics that modulate energy metabolism in the gut to regulate energy absorption, particularly in obesity treatment. The probiotics have engineered metabolic pathways that selectively inhibit lipid absorption by the host, thereby controlling energy intake. This approach enables targeted weight management by modulating the host's energy absorption mechanisms. The probiotics can be engineered to utilize lipids as a primary energy source, preventing excessive fat absorption and promoting weight regulation.

Source

The prevalence of type 2 diabetes (T2D) is increasing worldwide, with many patients developing long-term complications that affect their cardiovascular, urinary, alimentary, and other systems. A growing body of literature has reported the crucial role of gut microbiota in metabolic diseases, one of which, Akkermansia muciniphila, is considered the next-generation probiotic for alleviating metabolic disorders and the inflammatory response. Although extensive research has been conducted on A. muciniphila , none has summarized its regulation in T2D. Hence, this review provides an overview of the effects and multifaceted mechanisms of A. muciniphila on T2D and related diseases, including improving metabolism, alleviating inflammation, enhancing intestinal barrier function, and maintaining microbiota homeostasis. Furthermore, this review summarizes dietary strategies for increasing intestinal A. muciniphila abundance and effective gastrointestinal delivery.

Source

"Microbes and humans" is a topic that has been continuously studied over the past decade. Numerous recent studies show that quantitative and qualitative changes in the composition of the gastrointestinal tract microbiota have direct and indirect effects on metabolic changes in the host. Many countries are researching the microbiome and opportunities to influence health through environmental modification and introducing a probiotic, a metabiotic, or a synbiotic into the body. Considerable attention is paid to metabolic disorders and obesity, as these are issues that are becoming a progressive global epidemic. More than 2 billion people are overweight and obese, and many experts continue to look for promising methods to combat it. A special group of high risk for obesity is children. Statistics show a steady upward trend of obesity in children. Over the past 10 years, this trend has shown a rapid pace: from 6.7%, according to 2010, to 9.1% by 2020. In this context, Akkermansia muciniphila attracts special attention among all bacteria inhabiting the gastrointestinal tract due to its pot... Read More

Source

An important intestinal bacterial strain Akkermansia muciniphila contributes to improving carbohydrate and lipid metabolism, thus alleviating obesity symptoms. Here, we find that the Akk membrane protein Amuc_1100 regulates lipid metabolism in 3T3-L1 preadipocytes.

Source

Studies investigating the effect of multispecies synbiotic supplementation in obesity management are limited. The current study was performed to evaluate the effects of multispecies probiotics mixed with fructooligosaccharides on body composition, antioxidant status, and gut microbiome composition in overweight and obese individuals. We employed a randomized, double-blind, placebo-controlled trial design, in which 63 individuals aged 18-45 years were assigned to receive either a synbiotic supplement or placebo for 12 weeks. The synbiotic group consumed a daily dose of 37 109 colony-forming units (CFU) of a unique blend of seven different probiotics, along with 2 g of fructooligosaccharides, while the placebo group consumed 2 g of maltodextrin daily. Assessments were performed at baseline, week 6, and the end of the study. The results of the study indicated that synbiotic supplementation resulted in a significant reduction in waist circumference and body fat percentage compared to the baseline measurements, as observed at 12 weeks. At the end of the study, there were no significant ... Read More

Source

Obesity and obesity-associated disorders pose a major public health issue worldwide. Apart from conventional weight loss drugs, next-generation probiotics (NGPs) seem to be very promising as potential preventive and therapeutic agents against obesity. Candidate NGPs such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Anaerobutyricum hallii, Bacteroides uniformis, Bacteroides coprocola, Parabacteroides distasonis, Parabacteroides goldsteinii, Hafnia alvei, Odoribacter laneus and Christensenella minuta have shown promise in preclinical models of obesity and obesity-associated disorders. Proposed mechanisms include the modulation of gut flora and amelioration of intestinal dysbiosis, improvement of intestinal barrier function, reduction in chronic low-grade inflammation and modulation of gut peptide secretion. Akkermansia muciniphila and Hafnia alvei have already been administered in overweight/obese patients with encouraging results. However, safety issues and strict regulations should be constantly implemented and updated. In this review, we aim to explore (1) current knowl... Read More

Source

Previous data suggested that anti-obesity interventions, such as percutaneous electric neurostimulation and probiotics, could reduce body weight and cardiovascular (CV) risk factors by attenuation of microbiota alterations. However, potential mechanisms of action have not been unveiled, and the production of short-chain fatty acids (SCFAs) might be involved in these responses. This pilot study included two groups of class-I obese patients (N = 10, each) who underwent anti-obesity therapy by percutaneous electric neurostimulations (PENS) and a hypocaloric diet (Diet), with/without the administration of the multi-strain probiotic (Lactobacillus plantarum LP115, Lactobacillus acidophilus LA14, and Bifidobacterium breve B3), for ten weeks. Fecal samples were used for SCFA quantification (by HPLC-MS) in relation to microbiota and anthropometric and clinical variables. In these patients, we previously described a further reduction in obesity and CV risk factors (hyperglycemia, dyslipemia) after PENS-Diet+Prob compared to PENS-Diet alone. Herein, we observed that the administration of probi... Read More

Source

Compositions comprising specific strains of microbes, including Akkermansia, Bifidobacterium, and Clostridium species, for treating gastrointestinal disorders such as irritable bowel syndrome, inflammatory bowel disease, and Crohn's disease. The compositions are designed to modulate the gut microbiome and alleviate symptoms through mechanisms including pain reduction, improved gut motility, and enhanced barrier function.

Source

Abstract The current study aimed to explore the hypothesis that probiotic bacteria are significantly involved in the control of obesity using Wistar rats as the test group by feeding high fat diets (HFD) induced obesity. A total of four groups of rats were considered viz., normal pellet diet fed (NC), HFD fed (DC), HFD fed rats treated with probiotic fermented milk with soy protein isolate (SPI) and whey protein concentrate (WPC) (T1), HFD fed rats treated with probiotic fermented milk without WPC and SPI (T2). Body weight, abdominal fat weight, liver weight, serum Alanine aminotransferase level, and alkaline phosphatase level significantly ( p < 0.05) decreased after giving daily probiotic milk product supplementation with @ 2 ml per day for continuous 4 weeks. Whereas, C-reactive protein and Aspartate aminotransferase levels were not altered to a significant extent. The histology of the liver from the disease model group showed large lipid vacuoles deposited in the parenchyma cells. Product T2 confirmed fewer micro vesicular fatty changes and the appearance of T2 was better than... Read More

Source

Abstract It has been reported that Akkermansia muciniphila improves host metabolism and reduces inflammation; however, its potential effects on bile acid metabolism and metabolic patterns in metabolicassociated fatty liver disease (MAFLD) are unknown. In this study, we have analysed C57BL/6 mice under three feeding conditions: (i) a lowfat diet group (LP), (ii) a highfat diet group (HP) and (iii) a highfat diet group supplemented with A. muciniphila (HA). The results found that A. muciniphila administration relieved weight gain, hepatic steatosis and liver injury induced by the highfat diet. A. muciniphila altered the gut microbiota with a decrease in Alistipes , Lactobacilli , Tyzzerella , Butyricimonas and Blautia , and an enrichment of Ruminiclostridium , Osclibacter , Allobaculum , Anaeroplasma and Rikenella . The gut microbiota changes correlated significantly with bile acids. Meanwhile, A. muciniphila also improved glucose tolerance, gut barriers and adipokines dysbiosis. Akkermansia muciniphila regulated the intestinal FXRFGF15 axis and reshaped the construction of bile ... Read More

Source

Gut microbiota have been shown to be associated with the development of various diseases, and also to be used as disease markers or therapeutic targets. In Japan, fecal transplantation was clinically applied for inflammatory bowel diseases, but strict management including safety should be required, and the details mechanism of action have not been elucidated. In Nature medicine in 2018, oral administration of Akkermanisia muciniphila for obesity and glucose intolerance showed weight loss and improvement of glucose metabolism. A company has been established and oral tablets are being sold.

Source

The global prevalence of obesity, a chronically trophic metabolic disease, has garnered significant attention. The aim of this study was to investigate L-arabinose, a unique functional sugar that improves insulin resistance and intestinal environment while promoting probiotic proliferation, for its potential in preventing obesity induced by a high-fat and high-sugar (HFHS) diet in mice. The L-arabinose group was intragastrically administered with 0.4 mL 60 mg/(kg body weight) L-arabinose for 8 wk. The metformin group was intragastrically administered at 0.4 mL 300 mg/(kg body weight), as a positive control group. Treatment with L-arabinose resulted in a reduction of various obesity symptoms, such as prevented weight gain, increased liver-to-body ratio, decreased insulin, homeostasis model assessment for insulin resistance (HOMA-IR) index, and lipopolysaccharide (LPS) levels, as well as improved insulin resistance, reduced fat volume, inhibited hepatic steatosis, and repaired the pancreas. The L-arabinose treatment also improved lipid metabolism and inflammatory response, decreased th... Read More

Source

Obesity is closely associated with lipid accumulation and intestinal microbiota dysbiosis. It has been proved that probiotics supplement contributes to alleviate obesity. The objective of this study was to investigate the mechanism by which Lactobacillus plantarum HF02 (LP-HF02) alleviated lipid accumulation and intestinal microbiota dysbiosis in high-fat diet-induced obese mice.Our results showed that LP-HF02 ameliorated body weight, dyslipidemia, liver lipid accumulation, and liver injury in obese mice. As expected, LP-HF02 inhibited pancreatic lipase activity in small intestinal contents and increased fecal triglyceride levels, thereby reducing dietary fat hydrolysis and absorption. Moreover, LP-HF02 ameliorated the intestinal microbiota composition, as evidenced by the enhanced ratio of Bacteroides to Firmicutes, the decreased abundance of pathogenic bacteria (including Bacteroides, Alistipes, Blautia, and Colidextribacter) and the increased abundance of beneficial bacteria (including Muribaculaceae, Akkermansia, Faecalibaculum, and Rikenellaceae_RC9_gut_group). LP-HF02 also incr... Read More

Source

<i>Akkermansia muciniphila</i> (<i>A. muciniphila</i>) play an important in ameliorating obesity but is not allowed for direct consumption in most countries. To date, microbiota-directed foods selectively promote the targeted human gut microbes, providing a strategy for <i>A. muciniphila</i> enhancement. Multiple studies have indicated the potential regulation of the polyphenol on <i>A. muciniphila</i>. Therefore, a polyphenol screening based on <i>A. muciniphila</i> upregulation was performed in mice. Chlorogenic acid (CGA) exhibited a greater response to <i>A. muciniphila</i> upregulation. Furthermore, we found that CGA did not directly promote <i>A. muciniphila</i> growth or mucin secretion. Microbiome and metabolomics revealed that the increased abundance of <i>A. muciniphila</i> resulted from the inhibition of CGA on <i>Desulfovibrio</i> and <i>Alistipes</i> and the influence of docosahexaenoic acid, -hydroxybutyrate, and N-acetyl-lactosamine. Finally, to confirm the regulation of CGA on <i>A. muciniphila</i> under disease conditions, high-fat diet-fed mice were established. Th... Read More

Source

A next-generation probiotic strain, Akkermansia muciniphila EB-AMDK27, that inhibits inflammatory response by reducing or inhibiting the release of inflammatory factors, and is effective in treating inflammatory disease, particularly bowel inflammation, by maintaining the stability of intestinal microbiota. The strain also suppresses appetite by stimulating the secretion of appetite suppressant hormones.

Source

Compositions and methods for treating liver disorders by administering a consortium of isolated and purified microbial populations that improve gut function and reduce liver enzyme levels. The microbial populations, which can include species such as Akkermansia muciniphila and Faecalibacterium prausnitzii, are administered in an effective amount to reduce serum levels of liver enzymes AST and ALT by at least 5 IU/L. The compositions can be formulated in an ingestible form and administered orally, and can be used to treat a range of liver disorders including nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and cirrhosis.

Source

Akkermansia muciniphila is a Gram-negative anaerobic mucus-layer-degrading bacterium that colonizes the intestinal mucosa of humans and rodents. Metagenomic data have shown an inverse correlation between the abundance of A. muciniphila and diseases such as inflammatory bowel disease (IBD), obesity, and diabetes. Thus, in recent decades, the potential of this bacterium as an immunomodulatory probiotic for autoimmune and chronic inflammatory diseases has been explored in experimental models. Corroborating these human correlation data, it has been reported that A. muciniphila slows down the development and progression of diabetes, obesity, and IBD in mice. Consequently, clinical studies with obese and diabetic patients are being performed, and the preliminary results are very promising. Therefore, this mini review highlights the main findings regarding the beneficial roles of A. muciniphila and its action mechanisms in autoimmune and chronic inflammatory diseases.

Source

Akkermansia muciniphila is a well-known bacterium with the ability to degrade mucin. This metabolic capability is believed to play an important role in the colonization of this bacterium in the gut. In this study, we report the identification and characterization of a novel Akkermansia sp. DSM 33459 isolated from human feces of a healthy donor. Phylogenetic analysis based on the genome-wide average nucleotide identity indicated that the Akkermansia sp. DSM 33459 has only 87.5% similarity with the type strain A. muciniphila ATCC BAA-835. Akkermansia sp. DSM 33459 showed significant differences in its fatty acid profile and carbon utilization as compared to the type strain. The Akkermansia sp. DSM 33459 strain was tested in a preclinical obesity model to determine its effect on metabolic markers. Akkermansia sp. DSM 33459 showed significant improvement in body weight, total fat weight, and resistin and insulin levels. Interestingly, these effects were more pronounced with the live form as compared to a pasteurized form of the strain. The strain showed production of agmatine, suggesting... Read More

Source

Akkermansia muciniphila has been widely accepted as part of the next generation of probiotics. However, most current studies on A. muciniphila have focused on the application of type strain BAA835 T in the treatment of diseases, while few studies have reported on the genomic specificity, population structure, and functional characteristics of A. muciniphila species.

Source

Obesity and overweight are closely related to diet, and the gut microbiota play an important role in body weight and human health. The aim of this study was to explore how Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 supplementation alleviate obesity by modulating the human gut microbiome. A randomized, double-blind, placebo-controlled study was conducted on 72 individuals with overweight. Over a 12-week period, probiotic groups consumed 1 1010 colony-forming units of HY7601 and KY1032, whereas the placebo group consumed the same product without probiotics. After treatment, the probiotic group displayed a reduction in body weight (p < 0.001), visceral fat mass (p < 0.025), and waist circumference (p < 0.007), and an increase in adiponectin (p < 0.046), compared with the placebo group. Additionally, HY7601 and KY1032 supplementation modulated bacterial gut microbiota characteristics and beta diversity by increasing Bifidobacteriaceae and Akkermansiaceae and decreasing Prevotellaceae and Selenomonadaceae. In summary, HY7601 and KY1032 probiotics exert anti-obesity... Read More

Source

Probiotic strain that improves blood glucose homeostasis, lipid profile and body fat distribution after dietary intervention. The strain is characterized by a 16S rRNA gene Sanger sequencing to the closest species identity as Akkermansia muciniphila (99.85% similarity).

Source

Abstract. Obesity is a condition of excess fat accumulation due to an imbalance of energy intake and energy expenditure over a long period of time. According to the WHO, a person is diagnosed overweight if their Body Mass Index (BMI) 23-24,9 and obese if IMT 30. Probiotic consumption is one of management to encountered that condition. Probiotics have physiological function that contribute to food intake and appetite, weight loss, and metabolic function via gut microbiota. The purpose of this study was to determine the effectiveness of consuming probiotics on the body weight in adult obese conditions. This study was Scoping Review, by searching for articles from the PubMed, Springer Link, and Science Direct databases with keywords used probiotic and body weight and adult obesity randomized controlled trial ini the period 2019-2021. Articles that meet the inclusion criteria are 308 articles and those that are included in the exclusion criteria are 303 articles. From the results of the feasibility test based on on PICOS, 4 articles were obstained. The results of the analysis of 4 artic... Read More

Source

Akkermansia muciniphila strain SNUG-61027 (KCTC 13530BP) for suppressing appetite and preventing metabolic diseases, comprising a novel mechanism of action that enhances brown fat activity and induces secretion of the appetite-regulating hormone GLP-1, dependent on host IL-6 cytokine. The strain and its culture solution, supernatant, extract, or fraction thereof can be used to treat metabolic diseases such as obesity, diabetes, and cardiovascular disease.

Source

Akkermansia muciniphila (A. muciniphila) is a mucin-degrading bacterium that commonly lives in the intestinal mucus layer. It is normally detected in human faecal specimens and is one of the few bacteria potentially associated to obesity development. In this narrative review, possible mechanisms that support how A. muciniphila is implicated in the pathogenesis of obesity and metabolic-associated disease are described with the evaluation of its role as an intermediary or independent agent whose manipulation could be useful in the management of metabolic disorders. The ampleness of A. muciniphila is notably diminished in obesity, type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), cardiometabolic diseases and low-grade inflammation. Furthermore, an inverse relationship between A. muciniphila, body weight and insulin sensitivity has been observed in both humans and animals. Antidiabetic drugs, gastric bypass surgery, prebiotics and biologically active compounds, such as polyphenols or saponins, have been shown to be associated with A. muciniphila relative abundance and thu... Read More

Source

Akkermansia muciniphila, the sole representative bacteria of the phylum Verrucomicrobia in the human gut, is an important link between dietary fiber and host health. Recently, A. muciniphila and its active components have been proven to play an important role in ameliorating metabolic diseases. Interestingly, a great many studies have demonstrated dietary fiber delays the development of metabolic diseases and attenuates immune response by increasing gut abundance of A. muciniphila, whereas dietary fibers regulating this bacterial level exert inconsistent trends, with either upregulation or downregulation, in some diseases such as inflammatory diseases and liver steatosis. This review focuses on the modulatory effect of dietary fibers with different types and sources on the abundance of A. muciniphila in the gut, the relevant influence on host health, and the possible mechanisms of the modulation.

Source

Diabetes is a chronic condition characterized by a hyperglycemia increasing exponentially and the direct cause of more than 1.5 million deaths worldwide. The increase interest in the study of the gut microbiome within the context of diabetes has paved the way for the development and use of probiotics for the different types of diabetes: type 1 diabetes, type 2 diabetes, gestational diabetes and other specific types of diabetes. The use of probiotics is effective for decreasing hyperglycemia, particularly fasting blood glucose levels and HbA1c, but also HOMA-IR with conventional probiotics. However, the results more promising nowadays belong from the next generation probiotics, with the case of Akkermansia muciniphila as the main example. Thus, we will discuss the knowledge about the use of probiotics in the prevention and management of the different types of diabetes, with a special interest on the development of this field from the knowledge collected from gut microbiome studies.

Source